KARTOS THERAPEUTICS is a clinical stage
biopharmaceutical company with an investigational
MDM2 inhibitor (navtemadlin)

Leadership Team

Jesse McGreivy, MD

CEO / CMO

Beth Mechling

COO

Todd Covey

CSO

Peter Carbonaro

SVP, CMC

Greg Slatter, PhD

SVP, Clinical Pharmacology

Scott Sandler

SVP, Finance

John Mei

VP, Clinical Operations

Patricia Ryan, PhD

VP, Regulatory Affairs

Cecile Krejsa, PhD

VP, Translational Medicine

Reg Myers

SVP, Strategy & Business Development

Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer.

Executive Chairman

Wayne Rothbaum

President at Quogue Capital LLC

Wayne Rothbaum is president of Quogue Capital LLC, a single-family office private equity fund focused on investing and supporting small to midcap life sciences companies. In 2016, Mr. Rothbaum co-founded Kartos Therapeutics following the in-license of an investigational MDM2 inhibitor from Amgen. Mr. Rothbaum began his career at The Carson Group, a strategic consulting firm, where he managed its life sciences practice and boutique investment bank Evolution Capital. Following The Carson Group’s sale to Thomson Reuters in 2001, he started Quogue Capital, through which he has invested in and founded numerous public and private life sciences companies. In 2012, Mr. Rothbaum co-founded, and was the Executive Chairman of Acerta Pharma, a private life sciences company he later sold to AstraZeneca. Acerta’s lead drug, Calquence (acalabrutinib) was approved by the FDA for mantle cell lymphoma in 2017 and CLL in 2020. In 2016, Mr. Rothbaum took a leadership role in transforming Lion Biosciences (Iovance, NASDAQ: IOVA), restructuring and reorganizing its Board of Directors, senior management and overall clinical operations and strategy. Currently, Mr. Rothbaum is a board member and one of its largest shareholders. More recently, in 2019 he co-founded Telios Pharma after licensing a novel targeted therapy from Merck KGaA to treat selected myeloid blood cancers. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his MA in international economics from The George Washington University. He is listed as an inventor on many scientific patents and is published in numerous medical journals, including the NEJM, the Lancet and the Journal of Clinical Oncology.

Board of Directors

Iain Dukes, MA DPhil

Venture Partner at OrbiMed Advisors

Iain Dukes is currently Chairman of Iovance Biotherapeutics (NASQ:IOVA) and CEO of Theseus Pharmaceuticals and Viriom. He also serves on the Boards of KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ENYO, Kyn Therapeutics and ReViral.

Dr. Dukes previously served as Senior Vice-President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes was Vice-President of External Research & Development at Amgen, from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes holds Master of Jurisprudence and Doctorate of Philosophy degrees from the University of Oxford, a Master of Science degree in Cardiovascular Studies from the University of Leeds, and a Bachelor of Science degree in Pharmacology from the University of Bath.

David A. Piacquad

Independent Board Director

David A. Piacquad has been in the biopharmaceuticals business for nearly 40 years. He currently serves as a director on the boards of 3T Biosciences and Kartos Therapeutics. He retired from Amgen in 2022 after spending over a decade as the head of business development. During his tenure, Mr. Piacquad completed acquisitions and collaborations that significantly expanded Amgen's revenues, pipeline and international footprint. Additionally, he completed a number of deals that added major new research capabilities. Prior to Amgen, Mr. Piacquad was Senior Vice President, Business Development & Licensing at Schering-Plough Corporation. Before joining Schering-Plough, Mr. Piacquad spent more than 20 years at Johnson & Johnson, where he held a series of leadership roles in finance and business development. Mr. Piacquad holds a BA degree from Colgate University and an MBA from the Wharton School.

Roger Ulrich, PhD

Senior Advisor at Frazier Healthcare Partners & Scientific Advisor at BioGeneration Ventures

Dr. Ulrich is an entrepreneur and biotech executive with more than 35 years of operational and administrative experience in the pharmaceutical industry. He is currently a Senior Advisor to Frazier Healthcare Partners and a Scientific Advisor to BioGeneration Ventures, and is a member of several small pharma Board of Directors and Scientific Advisory Boards. Most recently he served as Chief Scientific Officer and a member of the Board of Directors at Acerta Pharma BV until the majority acquisition by AstraZeneca in 2016. Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., which was acquired by Gilead Sciences in 2011. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Dr. Ulrich holds several patents and has authored more than 125 publications. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.

Flavia Borellini, PhD

Independent Board Director

Dr. Borellini has over 25 years of executive management experience in the pharma/biotechnology industry, especially focused on global oncology drug development, from pre-clinical to on-market stage. Flavia is the retired Chief Executive Officer for Acerta Pharma, where she led the organization to the approval of Calquence for Mantle Cell Lymphoma; she also served as the Global Franchise Head, Hematology at AstraZeneca, with responsibility for the hematology portfolio in the Oncology Business Unit. During her career in the industry, Flavia led the global development, approval and launch of several oncology drugs, including a first in class EGFR T790M inhibitor (osimertinib, AstraZeneca), a first in class BRAF inhibitor (vemurafenib, Roche), and served as the program leader for a HER2 Positive Metastatic Breast Cancer inhibitor (trastuzumab) and a EGFR tyrosine kinase inhibitor (erlotinib) at Genentech. Flavia holds a PhD in Pharmaceutical Chemistry from the University of Modena (Italy), and completed her post-doctoral training at the NCI. Before joining industry, Flavia held a Research Assistant Professor position at Georgetown University in Washington DC. Flavia currently serves on the Board of Directors of Cantargia AB.

Board Observers

Carl L. Gordon, PhD, CFA

Managing Partner at OrbiMed Advisors

Carl L. Gordon, PhD, CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List". Carl received a PhD in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).

Erin Denny, PhD

Head of Oncology Search & Evaluation, Business Development, Amgen

Erin is currently a Director in Amgen’s Business Development group where she leads oncology search and evaluation. Her team is responsible for identifying external opportunities and conducting technical diligence for all licensing, collaboration and acquisition deals across oncology therapeutics. Since joining Amgen in 2015, Erin has led due diligence processes across several therapeutic areas and technology platforms within Business Development. She started her career as a Clinical Analyst at Doctor Evidence, a healthcare technology firm focused on developing a medical intelligence platform. Erin received her undergraduate degree from the University of Southern California (USC) and completed her PhD in Molecular and Cellular Biology at the City of Hope. She leads the Healthcare Businesswomen’s Association (HBA) Ambassador program at Amgen and holds an advisory board role for the Los Angeles chapter of the Association for Women in Science (AWIS).

Investors
Icon About Amgen Kartos Thera
Icon About Quogue Kartos Thera
Icon About Orbi Med Kartos Thera
Advisors
John C. Byrd, MD
The Gordon and Helen Hughes Taylor Professor and Chair, University of Cincinnati College of Medicine
James A. DeCaprio, MD
Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Jason Gotlib, MD, MS
Professor of Medicine, Stanford University School of Medicine
Claire Harrison, MD, FRCP, FRCPath
Professor of Myeloproliferative Neoplasms & Clinical Director of Haematology
Jean-Jacques Kiladjian, MD, PhD
Professor of Clinical Pharmacology & Head of the Clinical Investigation Center Hôpital Saint-Louis & Université Paris Diderot
Srdan Verstovsek, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Steve Knapper, DM, MRCP, FRCPath
Clinical Reader in Haematology, Cardiff University & Consultant Haematologist, University Hospital of Wales
Haifa Kathrin Al-Ali, MD
Ass. Professor of medicine & Head of the Krukenberg Cancer Center , University Hospital Halle (Saale)